| Name | Title | Contact Details |
|---|
Carefirst Blue Cross Blue Shield is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Technology and Patent Research International, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bolden Instrument is a Hamilton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.
Synarc enables its clients to demonstrate the efficacy of new therapies across a broad range of therapeutic areas through highly specialized medical imaging and molecular marker techniques.